Loading
A phase 1/2 trial of Gemcitabine, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Nelum Corp, active and no longer recruiting.
Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer is a phase 1/2 interventional study registered as NCT04827953 by Nelum Corp, with 28 participants enrolled, started 2021-09-01 and due to reach its primary completion in 2025-04. Interventions recorded: Gemcitabine, Nab paclitaxel, NLM-001, Zalifrelimab. Conditions listed: Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/